Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATXGet Free Report) have earned an average recommendation of “Buy” from the five brokerages that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation.

Several equities analysts have recently weighed in on CATX shares. Oppenheimer reissued an “outperform” rating and set a $1.50 price target (up from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. Cantor Fitzgerald assumed coverage on Perspective Therapeutics in a research note on Thursday, May 9th. They set an “overweight” rating for the company. Royal Bank of Canada started coverage on shares of Perspective Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $3.00 price objective on the stock. Lifesci Capital restated an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. Finally, B. Riley increased their price target on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a research report on Tuesday, April 9th.

Get Our Latest Analysis on CATX

Insider Buying and Selling

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was acquired at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.52% of the stock is currently owned by insiders.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. ZWJ Investment Counsel Inc. bought a new stake in shares of Perspective Therapeutics in the 1st quarter worth about $26,000. Simplicity Wealth LLC bought a new stake in shares of Perspective Therapeutics in the 1st quarter valued at approximately $40,000. Bleakley Financial Group LLC purchased a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $40,000. RIA Advisory Group LLC lifted its position in Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after buying an additional 99,293 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Perspective Therapeutics during the third quarter worth $42,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Performance

CATX opened at 1.74 on Tuesday. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -17.40 and a beta of 1.43. Perspective Therapeutics has a 52-week low of 0.21 and a 52-week high of 1.90. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02.

About Perspective Therapeutics

(Get Free Report

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Featured Articles

Analyst Recommendations for Perspective Therapeutics (NYSEAMERICAN:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.